Researchers from Case Western Reserve University and the Louis Stokes Cleveland VA Medical Center have presented new data demonstrating the efficacy of Clorox Healthcare Fuzion Cleaner Disinfectant. The study showed that Clorox Healthcare Fuzion Cleaner Disinfectant was as effective for killing Clostridium difficile (C. difficile) spores, methicillin-resistant Staphylococcus aureus, and carbapenem-resistant Escherichia coli as a standard bleach product, but was less damaging to surfaces and left less residue on surfaces.
Both bleach formulations reduced each of the pathogens by ≥6.0 log10CFU with a two minute contact time. An assessment of real-world materials compatibility of the products by repeated spray applications on a hospital mattress, formica bedside table, and textiles, found that Fuzion caused minimal to no adverse effects with up to 60 applications. Personnel using the products also reported that Fuzion left much less residue after use and was more tolerable than the standard bleach product.
(Image credit: Clorox Healthcare)
The research team led by Curtis J. Donskey, MD, Professor of Medicine at Case Western Reserve University and Infectious Disease Physician at the Louis Stokes Cleveland VA Medical Center, presented the findings as a poster abstract at the recent IDWeek conference in San Diego.
“Contaminated surfaces are a potential source for dissemination of pathogens in the healthcare environment,” says Donskey. “Our results confirm the product’s efficacy against clinically relevant healthcare pathogens and suggest that Fuzion may provide an alternative sporicidal disinfectant for facilities concerned about surface compatibility.”
Fuzion is the next generation of bleach and the first product of its kind to combine trusted bleach efficacy against tough-to-kill pathogens with the aesthetics required for broad use throughout healthcare facilities. Fuzion is EPA-registered to kill C. difficile spores in two minutes —the fastest kill time available — and 35 other pathogens in one minute.
